106 related articles for article (PubMed ID: 10896417)
21. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children.
Bowman RJ; Cope J; Nischal KK
Eye (Lond); 2004 Jan; 18(1):24-6. PubMed ID: 14707960
[TBL] [Abstract][Full Text] [Related]
22. Cystoid macular oedema associated with brimonidine therapy.
Kim P; Lertsumikul S
Clin Exp Ophthalmol; 2003 Apr; 31(2):165-6. PubMed ID: 12648055
[No Abstract] [Full Text] [Related]
23. [The ocular hypotensive effect and safety of 0.2% brimonidine].
Yu M; Li Y; Ge J
Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513
[TBL] [Abstract][Full Text] [Related]
24. Sensitization to and allergic contact dermatitis caused by Mirvaso(®) (brimonidine tartrate) for treatment of rosacea - 2 cases.
Bangsgaard N; Fischer LA; Zachariae C
Contact Dermatitis; 2016 Jun; 74(6):378-9. PubMed ID: 27133629
[No Abstract] [Full Text] [Related]
25. Allergic contact dermatitis caused by Mirvaso®, brimonidine tartrate gel 0.33%, a new topical treatment for rosaceal erythema.
Cookson H; McFadden J; White J; White IR
Contact Dermatitis; 2015 Dec; 73(6):366-7. PubMed ID: 26768997
[No Abstract] [Full Text] [Related]
26. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.
Sullivan-Mee M; Pensyl D; Alldredge B; Halverson K; Gerhardt G; Qualls C
J Ocul Pharmacol Ther; 2010 Aug; 26(4):355-60. PubMed ID: 20653479
[TBL] [Abstract][Full Text] [Related]
27. Systemic side effects of ophthalmic drops.
Levy Y; Zadok D
Clin Pediatr (Phila); 2004; 43(1):99-101. PubMed ID: 14968900
[TBL] [Abstract][Full Text] [Related]
28. Brimonidine/Timolol: a viewpoint by Richard Fiscella.
Fiscella R
Drugs Aging; 2006; 23(9):762-3. PubMed ID: 17020400
[No Abstract] [Full Text] [Related]
29. Charles Bonnet syndrome and brimonidine: comments.
Rahman I; Fernando B; Harrison M
Br J Ophthalmol; 2004 May; 88(5):724. PubMed ID: 15090439
[No Abstract] [Full Text] [Related]
30. Brimonidine-induced anterior uveitis and conjunctivitis: clinical and histologic features.
Nguyen EV; Azar D; Papalkar D; McCluskey P
J Glaucoma; 2008; 17(1):40-2. PubMed ID: 18303383
[TBL] [Abstract][Full Text] [Related]
31. Is brimonidine ophthalmic a safe therapy for infants?
Daubert GP
J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995
[TBL] [Abstract][Full Text] [Related]
32. Combination brimonidine and timolol.
Kerr NM; Gross KA; Tombleson M; Danesh-Meyer HV
Ophthalmology; 2010 Jan; 117(1):193-193.e1. PubMed ID: 20114113
[No Abstract] [Full Text] [Related]
33. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery.
Chen TC
J Cataract Refract Surg; 2005 Sep; 31(9):1707-12. PubMed ID: 16246772
[TBL] [Abstract][Full Text] [Related]
34. Transdermal clonidine skin reactions.
Prisant LM
J Clin Hypertens (Greenwich); 2002; 4(2):136-8. PubMed ID: 11927798
[TBL] [Abstract][Full Text] [Related]
35. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.
Craven ER; Walters TR; Williams R; Chou C; Cheetham JK; Schiffman R;
J Ocul Pharmacol Ther; 2005 Aug; 21(4):337-48. PubMed ID: 16117698
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
Fowler J; Jackson M; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M
J Drugs Dermatol; 2013 Jun; 12(6):650-6. PubMed ID: 23839181
[TBL] [Abstract][Full Text] [Related]
37. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.
Whitson JT; Ochsner KI; Moster MR; Sullivan EK; Andrew RM; Silver LH; Wells DT; James JE; Bosworth CF; Dickerson JE; Landry TA; Bergamini MV;
Ophthalmology; 2006 Aug; 113(8):1333-9. PubMed ID: 16877072
[TBL] [Abstract][Full Text] [Related]
38. Brimonidine/Timolol: a viewpoint by Francisco J. Goñi.
Goñi FJ
Drugs Aging; 2006; 23(9):762-3. PubMed ID: 17020402
[No Abstract] [Full Text] [Related]
39. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A
J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302
[TBL] [Abstract][Full Text] [Related]
40. Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma.
Loon SC; Liew G; Fung A; Reid SE; Craig JC
Clin Exp Ophthalmol; 2008 Apr; 36(3):281-9. PubMed ID: 18412600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
